Not everyone responds to statins, the standard treatment for people at risk of cardiovascular disease, so an alternative ...

CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

A stem cell treatment company claimed their stem cell therapies could reverse aging and treat, cure or prevent conditions ...

Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the donor's immune cells attack the recipient's tissues.

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

4, 2025 — Research has shown that a potential new targeted therapy for childhood brain ... Factor Unlocks New Potential in Stem Cell-Based Embryo Models Dec. 6, 2024 — Researchers have ...

BioSkryb Genomics, a Durham company focused on single-cell and ultra-low input multiomics, has introduced a new service called ResolveSEQ MRD, which allows more detailed classification and ...

PHC has partnered with CCRM to boost cell quality with advanced T-cell expansion solutions. Takeaway Points  PHC has ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...